150 related articles for article (PubMed ID: 22552267)
1. Plasma aldosterone is increased in class 2 and 3 obese essential hypertensive patients despite drug treatment.
Sarzani R; Guerra F; Mancinelli L; Buglioni A; Franchi E; Dessì-Fulgheri P
Am J Hypertens; 2012 Jul; 25(7):818-26. PubMed ID: 22552267
[TBL] [Abstract][Full Text] [Related]
2. [Profile on circadian blood pressure and the influencing factors in essential hypertensive patients after treatment].
Qiu YG; Yao XY; Tao QM; Zheng P; Chen JZ; Zhu JH; Zhang FR; Zheng LR; Zhao LL
Zhonghua Liu Xing Bing Xue Za Zhi; 2004 Aug; 25(8):710-4. PubMed ID: 15555399
[TBL] [Abstract][Full Text] [Related]
3. Plasma renin activity to plasma aldosterone concentration ratio correlates with night-time and pulse pressures in essential hypertensive patients treated with angiotensin-converting enzyme inhibitors/AT1 blockers.
Spannella F; Giulietti F; Balietti P; Borioni E; Lombardi FE; Ricci M; Cocci G; Landi L; Sarzani R
J Hypertens; 2017 Nov; 35(11):2315-2322. PubMed ID: 28614094
[TBL] [Abstract][Full Text] [Related]
4. Retrospective analysis of real-world efficacy of angiotensin receptor blockers versus other classes of antihypertensive agents in blood pressure management.
Petrella R; Michailidis P
Clin Ther; 2011 Sep; 33(9):1190-203. PubMed ID: 21885126
[TBL] [Abstract][Full Text] [Related]
5. Renoprotective effect of renin-angiotensin-aldosterone system blockade in patients with predialysis advanced chronic kidney disease, hypertension, and anemia.
Hsu TW; Liu JS; Hung SC; Kuo KL; Chang YK; Chen YC; Hsu CC; Tarng DC
JAMA Intern Med; 2014 Mar; 174(3):347-54. PubMed ID: 24343093
[TBL] [Abstract][Full Text] [Related]
6. Body mass index predicts plasma aldosterone concentrations in overweight-obese primary hypertensive patients.
Rossi GP; Belfiore A; Bernini G; Fabris B; Caridi G; Ferri C; Giacchetti G; Letizia C; Maccario M; Mannelli M; Palumbo G; Patalano A; Rizzoni D; Rossi E; Pessina AC; Mantero F;
J Clin Endocrinol Metab; 2008 Jul; 93(7):2566-71. PubMed ID: 18445663
[TBL] [Abstract][Full Text] [Related]
7. Plasma renin activity and angiotensin I and aldosterone concentrations in cats with hypertension associated with chronic renal disease.
Jensen J; Henik RA; Brownfield M; Armstrong J
Am J Vet Res; 1997 May; 58(5):535-40. PubMed ID: 9140564
[TBL] [Abstract][Full Text] [Related]
8. Plasma aldosterone and its relationships with left ventricular mass in essential hypertensive patients with the metabolic syndrome.
Mulè G; Nardi E; Cusimano P; Cottone S; Seddio G; Geraci C; Palermo A; Andronico G; Cerasola G
Am J Hypertens; 2008 Sep; 21(9):1055-61. PubMed ID: 18583983
[TBL] [Abstract][Full Text] [Related]
9. Different patterns of one-year evolution of microalbuminuria in hypertensive patients treated with different inhibitors of the renin-angiotensin system.
Cotter J; Oliveira P; Cunha P; Polónia J
Rev Port Cardiol; 2008 Nov; 27(11):1395-404. PubMed ID: 19227807
[TBL] [Abstract][Full Text] [Related]
10. Negative association between plasma aldosterone concentration/plasma renin activity and morning blood pressure surge in never-treated hypertensive patients.
Cho JS; Ihm SH; Jang SW; Chung WB; Choi YS; Shin DI; Seo SM; Park MW; Kim GH; Her SH; Kim CJ; Kim TH; Kang MK; Chang K; Park CS
Clin Exp Hypertens; 2014; 36(4):195-9. PubMed ID: 24678899
[TBL] [Abstract][Full Text] [Related]
11. Comparison between screening for primary aldosteronism with and without drug adjustment.
Hua Y; He Q
Blood Press; 2024 May; 33(1):2350981. PubMed ID: 38824645
[TBL] [Abstract][Full Text] [Related]
12. Renin-angiotensin-aldosterone system blockade in high-risk hypertensive patients: current approaches and future trends.
Gullapalli N; Bloch MJ; Basile J
Ther Adv Cardiovasc Dis; 2010 Dec; 4(6):359-73. PubMed ID: 20965951
[TBL] [Abstract][Full Text] [Related]
13. Usefulness of the alpha1-blocker doxazosin as a third-line antihypertensive drug.
Ohta Y; Tsuchihashi T; Onaka U; Eto K; Ueno M
Hypertens Res; 2007 Apr; 30(4):301-6. PubMed ID: 17541208
[TBL] [Abstract][Full Text] [Related]
14. Normokalemic hyperaldosteronism in patients with resistant hypertension.
Benchetrit S; Bernheim J; Podjarny E
Isr Med Assoc J; 2002 Jan; 4(1):17-20. PubMed ID: 11802302
[TBL] [Abstract][Full Text] [Related]
15. Beneficial long-term effect of aldosterone antagonist added to a traditional blockade of the renin-angiotensin-aldosterone system among patients with obesity and proteinuria.
Morales E; Gutiérrez E; Caro J; Sevillano A; Rojas-Rivera J; Praga M
Nefrologia; 2015; 35(6):554-61. PubMed ID: 26519114
[TBL] [Abstract][Full Text] [Related]
16. Effects of renin-angiotensin system inhibition on end-organ protection: can we do better?
Weir MR
Clin Ther; 2007 Sep; 29(9):1803-24. PubMed ID: 18035185
[TBL] [Abstract][Full Text] [Related]
17. β-Blocker withdrawal is preferable for accurate interpretation of the aldosterone-renin ratio in chronically treated hypertension.
Browne GA; Griffin TP; O'Shea PM; Dennedy MC
Clin Endocrinol (Oxf); 2016 Mar; 84(3):325-31. PubMed ID: 26300226
[TBL] [Abstract][Full Text] [Related]
18. Effect of combined angiotensin-converting enzyme and aldosterone inhibition on plasma plasminogen activator inhibitor type 1 levels in chronic hypertensive patients.
Tiryaki O; Usalan C; Buyukhatipoglu H
Nephrology (Carlton); 2010 Mar; 15(2):211-5. PubMed ID: 20470281
[TBL] [Abstract][Full Text] [Related]
19. Sibutramine is safe and effective for weight loss in obese patients whose hypertension is well controlled with angiotensin-converting enzyme inhibitors.
McMahon FG; Weinstein SP; Rowe E; Ernst KR; Johnson F; Fujioka K;
J Hum Hypertens; 2002 Jan; 16(1):5-11. PubMed ID: 11840224
[TBL] [Abstract][Full Text] [Related]
20. Shifting trends in the pharmacologic treatment of hypertension in a Nigerian tertiary hospital: a real-world evaluation of the efficacy, safety, rationality and pharmaco-economics of old and newer antihypertensive drugs.
Adigun AQ; Ishola DA; Akintomide AO; Ajayi AA
J Hum Hypertens; 2003 Apr; 17(4):277-85. PubMed ID: 12714973
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
